StockData
Valneva SE logo

Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30
$5.16−0.21 (-3.82%)

Close on Nov 20, 2026Market cap $447.73MP/E –Yield –

Valneva free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Valneva's free cash flow for the twelve months ending Jun 30, 2026 was -€58.04M. For fiscal 2025 it was -€57.31M. The highest annual figure on record is €118.80M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€57.31M–
FY2024Dec 31, 2024-€81.08M–
FY2023Dec 31, 2023-€216.98M–
FY2022Dec 31, 2022-€274.59M–
FY2021Dec 31, 2021-€15.33M-112.9%
FY2020Dec 31, 2020€118.80M–
FY2019Dec 31, 2019-€4.97M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€13.77M–
Q1 FY2026Mar 31, 2026-€560.00K–
Q4 FY2025Dec 31, 2025-€25.59M-551.6%
Q3 FY2025Sep 30, 2025-€18.11M–
Q2 FY2025Jun 30, 2025-€4.06M–
Q1 FY2025Mar 31, 2025-€9.55M–
Q4 FY2024Dec 31, 2024€5.67M–
Q3 FY2024Sep 30, 2024-€16.39M–
Q2 FY2024Jun 30, 2024-€37.44M–
Q1 FY2024Mar 31, 2024-€32.93M–
Q4 FY2023Dec 31, 2023-€71.79M–
Q3 FY2023Sep 30, 2023-€72.59M–
Q2 FY2023Jun 30, 2023-€44.42M–
Q1 FY2023Mar 31, 2023-€28.17M–
Q4 FY2022Dec 31, 2022-€62.60M-464.1%
Q3 FY2022Sep 30, 2022-€95.81M–
Q2 FY2022Jun 30, 2022-€79.94M-677.3%
Q1 FY2022Mar 31, 2022-€36.24M-216.0%
Q4 FY2021Dec 31, 2021€17.19M–
Q3 FY2021Sep 30, 2021-€77.60M–
Q2 FY2021Jun 30, 2021€13.85M–
Q1 FY2021Mar 31, 2021€31.23M–

More Valneva figures

See a number that looks wrong?